Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Dalbavancin safe, has...

    Dalbavancin safe, has high cure rate for bone, joint and orthopedic implant-related infection

    Written by Medha Baranwal Baranwal Published On 2019-06-03T19:20:03+05:30  |  Updated On 3 Jun 2019 7:20 PM IST
    Dalbavancin safe, has high cure rate for bone, joint and orthopedic implant-related infection

    SPAIN: Dalbavancin is a well-tolerated antibiotic (even at >2 doses) and is associated with a high cure rate of 65% to 76% for the treatment of osteoarticular infections (septic arthritis, spondylodiscitis, osteomyelitis, or orthopedic implant-related infection), suggests a recent study published in the journal Antimicrobial Agents and Chemotherapy.


    The authors, however, add, that these are preliminary data with a short follow-up, therefore, it is essential to gain more experience in the future in order to establish the most appropriate dose and frequency.


    Dalbavancin is a lipoglycopeptide with potent activity against Gram-positive microorganisms. It has an antibiotic spectrum similar to that of vancomycin, has a long half-life (180–240 hours, allowing weekly or biweekly dosing), and a favorable safety profile. Also, it achieves high concentrations in the bone making it an interesting alternative for the treatment of osteoarticular infections.


    L. Morata, University of Barcelona, Barcelona, Spain, and colleagues present a retrospective case series of 64 patients treated in 30 Spanish institutions in 2016 and 2017; all received dalbavancin for bone and joint (n=19) and orthopedic implant-associated infections (n=45).




    The most common pathogens were Staphylococcus epidermidis (n=30) and Staphylococcus aureus (n=14), 93% and 64% of which were methicillin-resistant. The patients had received other antibiotics for a median of 41 days (21–87), and the reasons for switching to dalbavancin included treatment simplification (53%), adverse events (25%), or failure of the previous regimen (22%).


    A median of five doses were administered; most patients received 1000 mg initially, and 500 mg doses at weekly intervals thereafter.


    Also Read: ICMR Antimicrobial Guidelines for Device Associated Infections

    Key Findings:




    • Adverse effects without the need for treatment discontinuation occurred in 11% of patients.

    • In 45 cases, infection was related to an orthopedic implant.

    • The implant material was retained in 23 cases, including that in 15 (65.2%) patients that were classified as cured and 8 (34.8%) that presented improvement.

    • In 21 cases, the implants were removed, including those in 16 (76.2%) cases that were considered successes, 4 (19%) cases were considered improved, and 1 (4.8%) case that was considered a failure.

    • Among the 19 cases without implants, 14 (73.7%) were considered cured, 3 (15.8%) were considered improved, and 2 (10.5%) were considered failures.

    • Rifampin was additionally administered in 18% and other antibiotics in 15%.


    Also Read: Oral antibiotics as good as intravenous in complex bone infections: NEJM

    To summarize, successful treatment was noted in 74% of bone and joint infections; the rate among implant-associated infections was 76% with retained implants and 65% in those who needed implant removal (median follow-up, 157 days).


    "The results show that dalbavancin is a well-tolerated antibiotic, even when >2 doses are administered, and is associated with a high cure rate," concluded the authors.


    For detailed study log on to DOI: 10.1128/AAC.02280-18

    Bonebone infectionsDalbavancindrug safetyhigh cure rateimplant-Associated InfectionsInfectionsjoint infectionsorthopedic implantorthopedic implant-related infectionosteoarticular infectionsosteomyelitisrifampinseptic arthritisspondylodiscitisStaphylococcus aureustreatmentwell tolerated
    Source : With inputs from Antimicrobial Agents and Chemotherapy

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok